Killing cancer cells by flipping the Bcl-2/Bax switch
Open accessAbstract
Impairment of apoptosis, the physiologic cell death process, is central to cancer development and renders tumors refractory to cytotoxic therapy. Bcl-2, the oncoprotein activated in follicular lymphoma, inhibits the conserved cell death pathway triggered by diverse cytotoxic agents, as do several close relatives. A small-molecule antagonist of these proteins has now been designed by Oltersdorf et al. Strikingly, ABT-737 sensitizes many tumors to cytotoxic agents and is effective as a single agent against certain lymphomas and solid tumors, provoking stable regression in some tumor xenografts. Hence, this work validates Bcl-2-like proteins as important new targets in cancer therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Bcl-2 family consists of anti-apoptotic and pro-apoptotic proteins that act synergistically as apoptotic switches, ultimately determining the cell's fate.
“This family consists of anti-apoptotic and pro-apoptotic proteins that act synergistically as apoptotic switches, ultimately determining the cell’s fate.358–360”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [360]
The citation lists haven’t been fetched yet
References 12 · Cited by 217
- Authors
- Cory, S., & Adams, J. M.
- Affiliations
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Cory, Suzanne
- Adams, Jerry M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 8
- Issue
- 1
- Pages
- 5-6
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1971183183
- Cited by
- 217
- References
- 12
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 5 · 2023: 15 · 2022: 6 · 2021: 5 · 2020: 11 · 2019: 9 · 2018: 6 · 2017: 13 · 2016: 7 · 2015: 7 · 2014: 8 · 2013: 14 · 2012: 11
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pharmacology › Flavonoids in Medical Research
- Keywords
- Bcl-2, Bax, apoptosis, ABT-737, BCL-2 inhibitor, follicular lymphoma, cancer therapy, tumor xenografts, cytotoxic drug sensitivity
- MeSH terms
- Biphenyl Compounds, Humans, Neoplasms, Nitrophenols, Piperazines, Sulfonamides, Apoptosis, Proto-Oncogene Proteins c-bcl-2, bcl-2-Associated X Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
